DOCSLIB.ORG

Issue 2 Jan-Mar 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Issue 2 Jan-Mar 2014 Collecting, Testing, Informing wedinos.org BULLETIN WEDINOS Quarterly Newsletter Issue 2 Jan-Mar 2014 The WEDINOS project has been designed for the collection and testing News from the Home Office of substances and, most importantly, dissemination via www.wedinos. 10th March 2014 - Changes to the scheduling org of pragmatic evidence based harm reduction information for users. of tramadol (prescription only medication). The WEDINOS aims to go beyond identification of novel substances, to address drug will be placed in Schedule 3 to accompany the harms associated with use of New Psychoactive Substances (NPS), new its Class C control. It will be exempted from the combinations of established drugs and NPS and Steroids & Image Enhancing requirements under the Misuse of Drugs (Safe Drugs (SIEDs). Custody) Regulations 1973. https://www.gov. uk/government/publications/letter-to-acmd-on- tramadol Headline Figures 12th February 2014 - Minister writes to Les • From Oct 2013 to March 2014 Iversen, chair of the ACMD, accepting the council’s recommendation to reclassify ketamine • 774 samples received as a Class B drug and announcing the intention • 71 samples rejected to consult on its scheduling. https://www.gov.uk/ • 703 samples analysed government/publications/government-response- • 169 substances identified in either combination or in isolation to-acmd-advice-on-ketamine • This quarter (Jan 2014 to March 2014) • 559 samples analysed • 140 substances identified in either combination or in isolation • 40% of psychoactive samples contained Amphetamines /Substituted WEDINOS reports 12 amphetamines, including: Methamphetamine, Ephedrine and Cathinones. new substances to the 34% contained Synthetic Cannabinoid Receptor Agonists. • 1/3 of SIEDs samples did not contain what they were believed to European Early • BRAIN – Since January 2014 there have been six hospitalisations in North Wales following the consumption of a substance known as Brain. Warning System WEDINOS was able to obtain and analyse a sample of this substance. The Monitoring Centre for Drugs and Upon analysis it was found to contain Amphetamine, Caffeine and MDPBP Drug Addiction (EMCDDA) holds a as major components, and BZP and di-(-phenylisopropyl)amine as minor master list of new drugs not previously components. identified or profiled, but are available in Europe. WEDINOS is pleased to be one ‘Legal highs, club drugs, designer drugs, new psychoactives...’ of the few providers of this information. The term new psychoactive substances has been legally defined by the European In the past quarter WEDINOS has Union as a new narcotic or psychotropic drug, in pure form or in a preparation, submitted the following12 notifications to that is not scheduled under the Single Convention on Narcotic Drugs of 1961 or the European Early Warning System: the Convention on Psychotropic Substances of 1971, but which may pose a public health threat comparable to that posed by substances listed in those conventions” • Mescaline NBOMe (Council of the European Union decision 2005/387/JHA) (N-(2-methoxybenzyl)-2-(3,4,5- trimethoxyphenyl)ethan-1-amine) Steroids and Image Enhancing Drugs (SEIDs) • para-Chloroamphetamine - SIEDs relates to a category of substances that include anabolic / androgenic amphetamine derivative steroids, peptide hormones, injectable tanning agents, diuretics, fat burners and aromatase inhibitors. • THJ-2201 - synthetic cannabinoid receptor agonist WEDINOS in the News - • 5F-MN-18 - synthetic cannabinoid receptor agonist The • BB-22 - synthetic cannabinoid Independent receptor agonist http://www.independent.co.uk/ voices/comment/a-lethal-ignorance- • JWH-175 - synthetic cannabinoid we-could-make-drugs-safer-we- choose-not-to-9162854.html receptor agonist • Coluracetam - nootropic drug • Diethyltryptamine, DET - psychedelic Tryptamine • Ethylone - stimulant • MDA - synthetic empathogen • Methoxphenidine - NMDA receptor BBC Newsbeat channel blocker http://www.bbc.co.uk/ • Phenazepam - benzodiazepine South Wales Argus newsbeat/25951290?utm_ http://www.southwalesargus. source=Drug+Testing+News&utm_ co.uk/news/gwentnews/10984527. medium=twitter Newport_drug_campaigners_ hit_back_over_criticism_of_ scheme/?ref=nt/ Findings… Who… Where a WEDINOS Effects Record was The average age of all sample submitted and gender completed; 81% providers was 29. Of those samples of submissions were from males. that were submitted as Mind Altering/ Where… The gender split for Mind Altering/ Psychoactive and age was stated the Psychoactive substances was 65% male average age 31. The age of sample Samples were submitted from all of the 7 to 35% were females. providers fell for Steroids & Image Welsh Health Boards. In relation to Steroids & Image Enhancing Drugs to 29. Enhancing Drugs, 94% were submitted by males, last quarter all SIED samples were submitted by males. Gender / Age profile of samples providers - Psychoactive Samples A 14 12 * 10 * 8 6 4 B 2 0 0-13 14-15 16-17 18-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 G Female Male *Females aged 20-24, eighteen samples were received in one package; these samples have been counted as one individual. Males aged 30-34, six samples were received in one package; these samples have been counted as one individual. F D C E Post analysis Class A increased Who… from 29 samples to 36. Class B also Breakdown of sample Reasons for purchase increased from 27 to 29; Class C and submissions by Health Board fell from 16 to 14. Substances that are 48% of samples were purchased as not controlled fell from 62 to 55. areas Steroids & Image Enhancing Drugs; In relation to the Mind Altering/ 41% were purchased for Mind Altering/ Psychoactive samples, 62 were A - 28 samples - Betsi Cadwaladr Psychoactive purposes. The remaining purchased as not controlled / legal. B - 2 samples - Powys Teaching 11% of samples did not have any reason Following analysis 7 contained a Class C - 95 samples - Aneurin Bevan for use stated. A substance and 4 Class B, based D - 8 samples - Cwm Taf on the highest classified substance E - 46 samples - Cardiff & Vale present. F - 38 samples - Abertawe Bro What… Morgannwg . Where the intended purchase G - 3 samples - Hywel Dda substance was listed as Mind Altering/ Temporary Class Drug Orders Psychoactive. 18 samples were received from The Misuse of Drugs Act 1971 has been undisclosed locations. 320 were received 29 samples were purchased in the belief amended to enable the Home Secretary to place from England, 3 from Northern Ireland, a new psychoactive substance causing sufficient that they were Class A substances 1 from Scotland and 7 from outside the concern about its potential harms under 27 Class B United Kingdom. temporary control by invoking a temporary class 6 Class C drug order. With the exception of the possession In relation to Welsh Health Boards, 62 were bought as not controlled / legal. offence, all the offences under the Misuse the highest proportion of samples came of Drugs Act 1971 will apply for substances from Aneurin Bevan University Health Proportion of controlled and not controlled by this measure. This new power Board, 95 samples were received, controlled / legal – Perceived and Actual became available on 15 November 2011. accounting for 17% of all samples (Psychoactive Substances) analysed. The Bristol postcode area 50% 46% submitted the highest proportion of 41% samples received from outside of Wales (47), equating to 8% of all samples analysed 27% 25% 22% 22% 20% 12% 10% 0% 0% 0% Class A Class B Class C TCDO Not controlled/Legal Perceived classification upon purchase Actual classification post analysis NB. Following analysis samples were categorised based on the highest classified substance present. Order of classification / control – Class A, B, C, Temporary Class Drugs Order, Not controlled. Most commonly identified substances Most commonly identified substances in all Mind Altering/Psychoactive samples. The most commonly identified psychoactive substance was Cocaine. 80 69 The most commonly identified psychoactive substance that is not 60 currently controlled was the synthetic 46 39 cannabinoid receptor agonists’ 40 5F-AKB48 and 5F-PB-22. 28 27 23 Levamisole was most popular 18 18 20 16 16 16 bulking/cutting agent identified; however, it exclusively appeared in samples that 0 also contained cocaine. In comparison Caffeine is found in far more samples, including those that contained Heroin, Cocaine Caffeine 5F-AKB48 5F-PB-22 Cannabis Diazepam MDMA, Amphetamine, Cocaine, Levamisole Benzocaine Mephedrone 5-MeO-DALT Mephedrone, Methamphetamine, Methiopropamine BZP, MDPBP, 5-MeO-DALT, and Cocaine, Mephedrone, Cannabis and Diazepam (Not prescribed) are controlled substances. Methiopropamine as major components. Testosterone Enanthate was the 5F-AKB48 and 5F-PB-22 are synthetic cannabinoid receptor agonists, 5-MeO-DALT is a psychedelic Tryptamine and Methiopropamine is a stimulant, these substances are not controlled. most commonly identified Steroid & Image Enhancing Drug, found in 34 Levamisole, Caffeine and Benzocaine commonly found bulking/cutting agents in psychoactive substances. samples. Mephedrone As we continue to hear anecdotal Ten most commonly identified reports of a potential fall in purity New Psychoactive Substances (NPS) only, levels of Mephedrone and a rise in the as per NPS definition practice of cutting Mephedrone with 30 28 bulking agents, we have again reviewed those samples where mephedrone 25 23 was a major component (n. 27). Of 20 18 18 those 78% contained Mephedrone 16 15 only. In the
Load more

Recommended publications
  • Rosscarrde2017.Pdf (4.959Mb)
    THE UNIVERSITY OF CENTRAL OKLAHOMA Edmond, OK Jackson College of Graduate Studies Method Development and Validation for Drug Identification and Confirmation by LC/MS-MS for Limited-specimen Cases A THESIS SUBMITTED TO THE GRADUATE FACULTY In partial fulfillment of the requirements For the degree of MASTER OF SCIENCE By Danielle Ross-Carr Edmond, Oklahoma 2017 DRUG IDENTIFICATION AND CONFIRMATION BY LC/MS-MS iii Acknowledgements I would like to express my appreciation to the Oklahoma State Bureau of Investigation Forensic Science Center and Andrea Swiech for allowing me the opportunity to complete this project and providing all necessary materials. A special thank you to Robert Weston for guiding me through the validation requirements and taking the time to work with me every step of the way. Thank you to Melissa Windham and Kourtney Heard for assisting with the required extractions and to Matt Stillwell for reviewing the completed data. To my committee chair, Dr. Thomas Jourdan, I would like to thank you for your support and guidance throughout the entirety of this project and for your feedback during the writing process. I would like to acknowledge my committee members, Dr. Wayne Lord and Dr. John Bowen for challenging me to think critically and preparing me to defend my project. To my family, friends, and co-workers, I would like to express my gratitude for all of your support and encouragement through this entire process. I cannot say thank you enough for your understanding and constant reassurance that I would make it to this point. Finally, to my wife, Kayla, for your unwavering support in everything that I do.
    [Show full text]
  • MMC International BV
    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • SEAC) Held on 01/10/2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar
    Minutes of the 554 th meeting ofthe State Level Expert Appraisal Committee (SEAC) held on 01/10/2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar. The 554 th meeting of the State Level Expert Appraisal Committee (SEAC) was held on 1st October 2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar. Following members attended the meeting: 1. Dr. Dinesh Misra, Chairman, SEAC 2. Shri S. C. Srivastav, Vice Chairman, SEAC 3. Shri Rajesh. I. Shah, Member, SEAC 4. Shri V. N. Patel, Member, SEAC 5. Dr. V. K. Jain, Member, SEAC 6. Shri A. K. Mule, Member, SEAC The regular agenda of Appraisal, Screening & Scoping/ToR, Reconsideration cases were taken up. The Committee considered the applications made by project proponents, additional details submitted as required by the SEAC/SEIAA and details furnished in the Form-1, PFR, EIA-EMP reports. Proposal No. Name and Address of the Unit Remarks 04 SIA/GJ/IND2/29059/2017 M/s. Dev Dyechem Industries EC – Plot No. C-1/324, Phase-I & II GIDC – Reconsideration Naroda, Ahmedabad. • PP remained absent in the EC – Appraisal presentation held on 01/10/2019. • After detailed discussion, Committee decided to defer the proposal and consider the same in one of the upcoming meeting of SEAC. 05 SIA/GJ/IND2/29678/2018 M/s. Apex Pharma EC – C-298/2/4, Saykha Industrial Estate, Reconsideration Saykha, Ta- Vagra, Dist -Bharuch. Category of the unit: 5(f) Project status: New • Project proponent (PP) submitted online application vide no. SIA/GJ/IND2/29678/2018 dated 30/04/19 for obtaining Environmental Clearance.
    [Show full text]
  • Methiopropamine (MPA) Critical Review Report Agenda Item 4.8
    Methiopropamine (MPA) Critical Review Report Agenda Item 4.8 Expert Committee on Drug Dependence Thirty-eighth Meeting Geneva, 14-18 November 2016 38th ECDD (2016) Agenda item 4.8 MPA Page 2 of 21 38th ECDD (2016) Agenda item 4.8 MPA Contents Acknowledgements .......................................................................................................................... 5 Summary .......................................................................................................................................... 6 1. Substance identification .................................................................................................... 7 A. International Nonproprietary Name (INN) ........................................................................ 7 B. Chemical Abstract Service (CAS) Registry Number .......................................................... 7 C. Other Chemical Names ...................................................................................................... 7 D. Trade Names ...................................................................................................................... 7 E. Street Names ...................................................................................................................... 7 F. Physical Appearance .......................................................................................................... 7 G. WHO Review History ......................................................................................................... 7 2.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Single Exposure to the Cathinones MDPV and Α-PVP Alters Molecular Markers of Neuroplasticity in the Adult Mouse Brain
    International Journal of Molecular Sciences Article Single Exposure to the Cathinones MDPV and α-PVP Alters Molecular Markers of Neuroplasticity in the Adult Mouse Brain Lucia Caffino 1 , Francesca Mottarlini 1 , Sabrine Bilel 2, Giorgia Targa 1 , Micaela Tirri 2 , Coralie Maggi 1, Matteo Marti 2,3,† and Fabio Fumagalli 1,*,† 1 Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy; lucia.caffi[email protected] (L.C.); [email protected] (F.M.); [email protected] (G.T.); [email protected] (C.M.) 2 Section of Legal Medicine and LTTA Center, Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (S.B.); [email protected] (M.T.); [email protected] (M.M.) 3 Collaborative Center for the Italian National Early Warning System, Department of Anti-Drug Policies, Presidency of the Council of Ministers, 44121 Ferrara, Italy * Correspondence: [email protected]; Tel.: +39-02-50318298 † Fumagalli and Matteo Marti share the seniorship. Abstract: Synthetic cathinones have gained popularity among young drug users and are widely used in the clandestine market. While the cathinone-induced behavioral profile has been extensively investigated, information on their neuroplastic effects is still rather fragmentary. Accordingly, we have exposed male mice to a single injection of MDPV and α-PVP and sacrificed the animals at different time points (i.e., 30 min, 2 h, and 24 h) to have a rapid readout of the effect of these psychostimulants on neuroplasticity in the frontal lobe and hippocampus, two reward-related brain regions.
    [Show full text]
  • NEWS 02 2020 ENG.Qxp Layout 1
    Polymers and fluorescence Balance of power 360° drinking water analysis trilogy Fluorescence spectroscopy LCMS-8060NX: performance of industrial base polymers and robustness without Automatic, simultaneous and compromising sensitivity rapid analysis of pesticides and speed CONTENT APPLICATION »Plug und Play« disease screening solution? – The MALDI-8020 in screening for Sickle Cell Disease 4 Customized software solutions for any measurement – Macro programming for Shimadzu UV-Vis and FTIR 8 Ensuring steroid-free food supplements – Identification of steroids in pharmaceuticals and food supplements with LCMS-8045 11 MSn analysis of nonderivatized and Mtpp-derivatized peptides – Two recent studies applying LCMS-IT-TOF instruments 18 Polymers and fluorescence – Part 2: How much fluorescence does a polymer show during quality control? 26 PRODUCTS The balance of power – LCMS-8060NX balances enhanced performance and robustness 7 360° drinking water analysis: Episode 2 – Automatic, simul- taneous and rapid analysis of pesticides in drinking water by online SPE and UHPLC-MS/MS 14 Versatile testing tool for the automotive industry – Enrico Davoli with the PESI-MS system (research-use only [RUO] instrument) New HMV-G3 Series 17 No more headaches! A guide to choosing the perfect C18 column 22 Validated method for monoclonal antibody drugs – Assessment of the nSMOL methodology in Global solution through the validation of bevacizumab in human serum 24 global collaboration LATEST NEWS Global solution through global collaboration – Shimadzu Cancer diagnosis:
    [Show full text]
  • 2021 SB 1738 by Senator Brodeur 9-01008B-21 20211738__ Page 1 of 34 CODING
    Florida Senate - 2021 SB 1738 By Senator Brodeur 9-01008B-21 20211738__ 1 A bill to be entitled 2 An act relating to controlled substances; amending s. 3 893.03, F.S.; excluding from Schedule I cannabis if it 4 is contained within a pharmaceutical product approved 5 by the United States Food and Drug Administration; 6 providing an effective date. 7 8 Be It Enacted by the Legislature of the State of Florida: 9 10 Section 1. Paragraph (c) of subsection (1) of section 11 893.03, Florida Statutes, is amended to read: 12 893.03 Standards and schedules.—The substances enumerated 13 in this section are controlled by this chapter. The controlled 14 substances listed or to be listed in Schedules I, II, III, IV, 15 and V are included by whatever official, common, usual, 16 chemical, trade name, or class designated. The provisions of 17 this section shall not be construed to include within any of the 18 schedules contained in this section any excluded drugs listed 19 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded 20 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical 21 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted 22 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt 23 Anabolic Steroid Products.” 24 (1) SCHEDULE I.—A substance in Schedule I has a high 25 potential for abuse and has no currently accepted medical use in 26 treatment in the United States and in its use under medical 27 supervision does not meet accepted safety standards.
    [Show full text]
  • EXECUTIVE SUMMARY Steroids
    EXECUTIVE SUMMARY PREFACE M/s Ratantray Pharmaceuticals Pvt. Ltd. is proposing a project for manufacturing of Vitamins, Steroids & Hormones. SITE DESCRIPTION The said project will come up at H1-174 RIICO, Shree Khatushyam Ji Industrial Area, Reengus, District-Sikar, Rajasthan. The total land available is 500 square metre. The complete land is under acquisition. PROJECTDESCRIPTION M/s Ratantray Pharmaceuticals Pvt. Ltd. is proposing a project for manufacturing of Vitamins, Steroids & Hormones. As per EIA Notification dated 14th Sept., 2006 and amended from time to time, the proposed project falls under Category “B”, Project or Activity 5(f) Synthetic organic chemical Industry. The project is submitted at SEIAA Rajasthan as the proposed project is in notified industrial area. The details of Raw materials are as shown in the table below: Table-1 List of Raw Material S. No. Raw Material Unit Quantity Standard Per Month Per Year (5.0kg batch size) (110kg/month) (Kg) 1 Cyanocobalamin Kg 5.00 100 1200 2 Methyl Iodide Kg 4.50 90 1080 3 Sodium Kg 5.50 110 1320 Borohydride 4 Chloroform Kg 98.00 1960 23520 5 Acetone Kg 60.00 1200 14400 6 Phenol Kg 25.00 500 6000 7 Methanol Kg 13.00 260 3120 The details of Raw materials are as shown in the table below: Table-2 List of Products S. No. Vitamins 1 Methylcobalamin ( Vitamin B12) 2 Hydroxocobalamin Acetate 3 Alfacalcidol (Vitamin D) 4 Ascorbic Acid (Vitamin C) 5 Calcitriol (Vitamin D3) 6 Ergocalciferol (Vitamin D2) 7 Paricalcitol (Vitamin D2) 8 Pyridoxal 5 Phosphate (Vitamin B6) Steroids 1 | Page 1 Beclomethasone
    [Show full text]
  • Injectable Steroids Oral Steroids Post Cycle Therapy Fat Burners Manufacturers Contact Us
    Blog Shopping Cart Wishlist My Account Checkout Search $0.00 Menu STEROIDS SHOP INJECTABLE STEROIDS ORAL STEROIDS POST CYCLE THERAPY FAT BURNERS MANUFACTURERS CONTACT US Injectable Steroids Shop Injectable Steroids SORT BY POPULARITY Search SOLD OUT INJECTABLE STEROIDS Deca Durabolin Equipoise HGH Masteron NPP INJECTABLE STEROIDS Parabolan Androxine $90.00 Primobolan Depot Sustanon 250 Testosterone Cypionate Testosterone Enanthate Testosterone Propionate Testosterone Suspension Trenbolone Acetate Trenbolone Enanthate Trenbolone Suspension Tri Tren Winstrol Depot ORAL STEROIDS INJECTABLE STEROIDS Anadrol Aquaviron Anavar $66.00 Dianabol Halotestin Methyltrienolone Moda됍nil Primobolan Proviron Superdrol Testosterone Undecanoate Turinabol Winstrol POST CYCLE THERAPY Anastrozole EQUIPOISE Boldebolin Cabergoline $60.00 Clomid Exemestane HCG HMG Letrozole Nolvadex FAT BURNERS Clenbuterol Cytomel T3 MANUFACTURERS EQUIPOISE Alpha Pharma Boldebolin (vial) Eminence Labs $55.00 Maxtreme Pharma SOLD OUT EQUIPOISE BoldePrime $69.00 EQUIPOISE Bold-Max $73.00 SOLD OUT EQUIPOISE Bold-One $39.00 SOLD OUT INJECTABLE STEROIDS CypoPrime $43.00 SOLD OUT DECA DURABOLIN DecaPrime $54.00 INJECTABLE STEROIDS Alphabolin $62.00 INJECTABLE STEROIDS Alphabolin (vial) $125.00 SOLD OUT INJECTABLE STEROIDS EnaPrime $43.00 HGH Eutropin 4 IU $55.00 HGH Humatrope $550.00 INJECTABLE STEROIDS Induject-250 $59.00 INJECTABLE STEROIDS Induject-250 (vial) $59.00 SOLD OUT INJECTABLE STEROIDS DrostoPrime $72.00 INJECTABLE STEROIDS
    [Show full text]